April 26, 2021
A combination therapy pairing Eisai’s multikinase inhibitor Lenvima (lenvatinib) and MSD’s PD-1 inhibitor Keytruda (pembrolizumab) was filed in Japan for an additional indication of advanced uterine body cancer, the two companies said on April 23. It is the second submission...read more